Antimalarial medication

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

Retrieved on: 
Monday, October 16, 2023
Congress, Medical Mycology, Antimalarial medication, TIMM, EEST, Biotechnology, EDT, Pharmaceutical industry, Aspergillus

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.

Key Points: 
  • JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.
  • Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
    Time: 3:35 p.m EEST / 8:35 a.m. EDT

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

SCYNEXIS to Participate in September Investor Conferences

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Antimalarial medication, Pharmaceutical industry

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

Key Points: 
  • JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Retrieved on: 
Wednesday, August 23, 2023
Regulation of therapeutic goods, Infection, Antimalarial medication, Clinical trial, Foot, ASX, FSE, COVID, Burn, 2018 Vuelta a España, Stage 1 to Stage 11, Erythema, Patient, Swelling, Observation, Genetically modified bacteria, Burns, TGA, Safety, RCE, Pharmaceutical industry

“We thank the West Australian Government for sponsoring this investigator-led topical burn wound infection trial,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “We thank the West Australian Government for sponsoring this investigator-led topical burn wound infection trial,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “The patient data received has paved the way to advance this new class of anti-infective as a topical application against deadly bacterial pathogens and a broad range of infectious diseases.
  • Endpoints of the trial include clinical wound assessment, graded for specific parameters such as erythema, hyper granulation, swelling, and discharge, and microbial cultures of wound swabs.
  • Stage 2 of the clinical trial is expected to be a randomized ‘head-to-head’ study in patients with infected burn wounds, where R327G will be compared to the current standard of care.

Lundquist Principal Investigator Dr. Michael Yeaman Awarded $11.5 Million NIAID/HHS Grant for Innovative Research To Understand and Solve Persistent Bloodstream Infections

Retrieved on: 
Tuesday, August 15, 2023
Vaccine, Infection, DNA, Duke University Hospital, Centers for Disease Control and Prevention, Genetics, TLI, Epigenomics, Public, National Institute of Allergy and Infectious Diseases, MRSA, Immunity, Biomedical Research, Hope, Research, Antimalarial medication, Staphylococcus, Doctor of Philosophy, Bangladesh Technical Education Board, CDC, Harbor–UCLA Medical Center, Molecular medicine, Principal investigator, Division, Risk, Immune system, Nightfall and Other Stories, Biological engineering, NIAID, Principal, UCLA, United States Department of Health and Human Services, NIH, Bloodstream infections, Pharmaceutical industry, Health, Medicine, U19

In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.

Key Points: 
  • In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.
  • The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.
  • Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.
  • “We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman.

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Workforce, Mucorales, GSK, Hansoh Pharmaceutical, IV, SG, Ibrexafungerp, General Administration of Sport of China, Biotechnology, NDA, NIH, Candidiasis, Global health, Tablet, End-user license agreement, Silicon, Congress, Antimalarial medication, ECCMID, VVC, Investment, European, License, Research, IND, NMPA, Infection, Auris, FURI, Pharmaceutical industry, Cryptocurrency

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
  • On June 21, 2023, SCYNEXIS announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
  • Selling, general & administrative (SG&A) expense for Q2 2023 decreased to $7.5 million from $15.8 million for Q2 2022.
  • Total other income was $5.7 million for Q2 2023, versus total other income of $8.4 million for Q2 2022.

Andira Pharmaceuticals’ US Patent Allowed in Breakthrough Therapeutic Treatment to Address Deadly Antibiotic-Resistant Infections

Retrieved on: 
Thursday, August 10, 2023
Patent, Daptomycin, United States patent law, IP, Pharmacotherapy, Antimalarial medication, Hospital, Fungal infection, United States capital, Pharmaceutical industry

Andira has announced that it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) for US Patent Application No.

Key Points: 
  • Andira has announced that it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) for US Patent Application No.
  • 17/589,588 “Antibiotic Cannabinoid-Terpene Formulations.” Andira Pharmaceuticals is the sole exclusive worldwide licensee of the patent.
  • “The allowance of this patent is an important milestone toward successfully addressing hospital-acquired infections that are resistant to antibiotics.” said Dr. Dana Lambert, President and CEO of Andira.
  • “Andira has an extensive global IP portfolio, and this issuance from USPTO is another significant milestone achievement for Andira.

Emergence of Multidrug-Resistant Strains Steers Global Tuberculosis Therapeutics Market Towards $2.99 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Infectious Diseases, Hospitals, Pharmaceutical, Health, Route of administration, Tuberculosis, Therapy, Prevalence, Antimalarial medication, Dosage form, TB, Linezolid, World Health Organization, COVID-19, Miliary tuberculosis, Active, USD, Market, BCG, Incidence, Mass drug administration, Guideline, Patient, Mortality, WHO, Death, Moxifloxacin, Pharmaceutical industry

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.

Key Points: 
  • The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.
  • The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis.
  • The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021.
  • Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market.

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

Retrieved on: 
Thursday, July 20, 2023
Biotechnology, NDA, Candidiasis, Tablet, Antimalarial medication, VVC, Patient, National Medical Products Administration, NMPA, Pharmaceutical industry, Ibrexafungerp

In February 2021, SCYNEXIS entered into an agreement for the development and commercialization rights for oral ibrexafungerp in the greater China region with Hansoh Pharma.

Key Points: 
  • In February 2021, SCYNEXIS entered into an agreement for the development and commercialization rights for oral ibrexafungerp in the greater China region with Hansoh Pharma.
  • Under the terms of the agreement, Hansoh is responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China.
  • Ibrexafungerp, once approved, is expected to become a new, first in class anti-fungal treatment for Chinese patients with vulvovaginal candidiasis (VVC).
  • The acceptance of the NDA brings us one more step closer to making this novel and differentiated antifungal available to patients in Greater China.”

Ringworm fungal infections are common in the US and are becoming increasingly resistant to treatment – 6 questions answered

Retrieved on: 
Thursday, June 29, 2023
Infection, Hair, Human, Conversation, Epidermophyton, Griseofulvin, Skin, Fungal infection, Prevalence, Dermatophytosis, Hyperhidrosis, Atmosphere, Hair loss, Cracked, Finger, Health, Nail, Clothing, The, Livestock, Global health, Hypha, Lupus, Cell, Fungus, New York State Department of Health, Rash, CDC, Athlete, Plant, Death, Antimalarial medication, Helminthiasis, Terbinafine, Animal, Soil, Population, Patient, Wrestling, Immune system, Autoimmune disease, Pet, Yeast, World Health Organization, Growth, Tolnaftate, Bacteria, Center, Research, World, Microsporum, Itraconazole, Pharmaceutical industry, Vaccine, Sulfur, Truffle, Self storage, Cosmetics, Fungiculture, Sports equipment, Trichophyton, Clotrimazole

The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.

Key Points: 
  • The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.
  • Similar to the way bacteria have developed resistance to antibiotics, fungal infections throughout the world are becoming more drug-resistant and more deadly.

1. What is ringworm and how common is it?

    • However, a ringworm infection is a common infection of the skin caused by a fungus.
    • Experts state that about 20%-25% of the population will experience a ringworm infection at any given time.
    • Research shows that there are up to 40 types of fungus that can cause these ringworm infections, with the most common types being from the genuses Trichophyton, Microsporum or Epidermophyton.
    • Medical terms for ringworm are “tinea” and “dermatophytosis.” Tinea and dermatophytosis are synonyms for a contagious fungal infection of the skin.

2. How can you recognize ringworm?


    The hair, skin and nails of either fingers or toes are the likely landing spots for a ringworm infection. Signs and symptoms of an infection usually depend on which part of the body is affected, but generally may include hair loss and red, scaly, cracked skin. However, the most well-known sign that gives this infection its ironic and misplaced name – ringworm – is the hallmark ring-shaped rash.

3. How does ringworm spread?

    • Fungi can grow in two forms: yeasts, which are single round cells, and molds, which are made up of many cells forming long, thin, hairlike threads called hyphae.
    • Some of them can exhibit both forms of growth and thrive in decaying organic material like soil or a plant.
    • Ringworm occurs more frequently in tropical areas and during hot, humid summers.

4. How can you reduce the likelihood of getting it?

    • Some of the best ways to reduce or prevent a ringworm or other fungal infection include: – Wash hands with soap and warm water.
    • – Wear shoes and socks that are made of lightweight, breathable materials to reduce moisture.
    • – Avoid walking barefoot in wet or humid areas like locker rooms or public showers.

5. What treatments are there?

    • There are several treatment options, including antifungal medications prescribed by a physician or dermatologist or over-the-counter products sold as a cream or ointment.
    • Finally, in some cases a person may need to use antifungal shampoo and soap to clean themselves and sterilize bedding and clothing.

6. Why is antifungal resistance a growing problem?

    • Antimicrobial resistance, including antifungal resistance, is an ongoing global emergency.
    • Experts estimate that drug-resistant infections caused roughly 1.3 million deaths around the world in 2019.
    • Experts believe that inappropriate use of topical antifungal and corticosteroid medications is likely driving its spread.